Table 3 Clinical trials targeting the CAFs
Target | Drug | Combination | Condition | Phase | Status | Trial number |
|---|---|---|---|---|---|---|
FAP-expressing cells | Simlukafusp alfa (RO6874281) | Atezolizumab and chemotherapy | Advanced and/or Metastatic Solid Tumors | II | Completed | NCT03386721 |
| Â | Simlukafusp alfa (RO6874282) | Trastuzumab and Cetuximab | Solid tumor | I | Active, not recruiting | NCT02627274 |
| Â | Sibrotuzumab (BIBH 1) | No | Metastatic Colorectal Cancer | II | Completed | NCT02198274 |
| Â | FAP-specific CAR-T | No | FAP-Positive Malignant Pleural Mesothelioma | I | Completed | NCT01722149 |
| Â | Â | No | Malignant Solid Tumors | I | Recruiting | NCT03932565 |
Vitamin D receptor | Calcipotriol | 5-fluorouracil | Skin cancer precursor immunotherapy | I | Completed | NCT02019355 |
| Â | Paricalcitol | Docetaxel, ixabepilone, and paclitaxel | Metastatic Breast Cancer | I | Completed | NCT00637897 |
| Â | Paricalcitol | Gemcitabine, Nab-paclitaxel | Metastatic Pancreatic Cancer | I/II | Recruiting | NCT03520790 |
Vitamin A metabolism | ATRA | Gemcitabine and Nab-paclitaxel | Pancreatic Adenocarcinoma | I | Completed | NCT03307148 |
| Â | Â | No | Advanced Adenoid Cystic Carcinoma | II | Completed | NCT03999684 |
| Â | Â | Paclitaxel and Cisplatin | Non-small Cell Lung Cancer | III | Unknown | NCT01041833 |
|  |  | Interferon-Alpha 2a | Recurrent Neuroblastoma or Wilms’ Tumor | II | Completed | NCT00001509 |
TGFβ | LY2157299(galunisertib) | Nivolumab | Solid Tumor; Non-Small Cell Lung Cancer; Hepatocellular Carcinoma Recurrent | I/II | Completed | NCT02423343 |
| Â | Â | Gemcitabine | Advanced or Metastatic Unresectable Pancreatic Cancer | I/II | Completed | NCT01373164 |
| Â | Â | Sorafenib, Ramucirumab | Hepatocellular Carcinoma | II | Completed | NCT01246986 |
| Â | Â | Durvalumab | Metastatic Pancreatic Cancer | I | Completed | NCT02734160 |
| Â | Â | Radiation, Temozolomide | Malignant Glioma | I/II | Completed | NCT01220271 |
| Â | Â | Capecitabine, Fluorouracil | Rectal Cancer | II | Active, not recruiting | NCT02688712 |
| Â | Â | Lomustine | Glioblastoma | II | Active, not recruiting | NCT01582269 |
| Â | Minnelide | No | Advanced Gastrointestinal Tumors | I | Completed | NCT01927965 |
| Â | Â | No | Pancreatic Cancer | II | Completed | NCT03117920 |
| Â | AP 12,009 | No | Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms | I | Completed | NCT00844064 |
CXCR4 | Motixafortide (BL-8040) | Pembrolizumab, chemotherapy | Metastatic Pancreatic Cancer | II | Active, not recruiting | NCT02826486 |
| Â | AMD3100 (plerixafor) | No | Advanced Pancreatic, Ovarian and Colorectal Cancers | I | Completed | NCT02179970 |
| Â | Â | Mozobil | Children Cancer, Solid Tumor | II | Completed | NCT01225419 |
Hedgehog | Itraconazole | No | Basal Cell Carcinoma (BCC), Skin Cancer | II | Completed | NCT01108094 |
| Â | Vismodegib | No | Basal Cell Carcinoma | II | Completed | NCT01700049 |
| Â | Â | Gemcitabine hydrochloride | Pancreatic Cancer | I/II | Completed | NCT01064622 |
| Â | Â | Gemcitabine Hydrochloride | Pancreatic Cancer | II | Completed | NCT01195415 |
| Â | Â | Cisplatin, Cixutumumab, Etoposide | Lung cancer | II | Completed | NCT00887159 |
| Â | LDE225 (sonidegib) | Etoposide and Cisplatin | Lung cancer | I | Completed | NCT01579929 |
| Â | Â | Paclitaxel | Solid Tumor | I | Completed | NCT01954355 |
| Â | Â | Docetaxel | Breast cancer | I | Completed | NCT02027376 |